Table 2.
HIV-related markers while on immune checkpoint inhibitor therapy
| Patient | cART regimen | plasma HIV viral load (copies/mL) at baseline |
plasma HIV viral load (copies/mL) at 24 weeks |
CD4+ T cell count (cells/μL) at baseline |
CD4+ T cell count(cells/μL) at 24 weeks |
|---|---|---|---|---|---|
| 1 | TDF + LAM + EFV | < 40 | NA | 171 | 159 |
| 2 | TDF + LAM + DTG | Not detected | Not detected | 156 | 137 |
| 3 | FTC + TAF + RAL | < 40 | Not detected | 120 | 177 |
| 4 | TDF + LAM + EFV | Not detected | NA | 375 | NA |
| 5 | TDF + LAM + EFV | NA | NA | NA | NA |
| 6 | TDF + LAM + DTG | 159 | NA* | 317 | NA* |
| 7 | TDF + LAM + EFV | < 40 | Not detected | 208 | 337 |
| 8 | TDF + DTG + FTC | 198 | 43.8 | 60 | NA |
| 9 | TDF + LAM + DTG | NA | NA* | 156 | NA* |
| 10 | TDF + LAM + EFV | NA | Not detected | NA | 824 |
| 11 | TDF + LAM + DTG | 2.18E + 5 | NA* | 120 | NA* |
| 12 | TDF + LAM + EFV | NA | NA* | 55 | NA* |
| 13 | BIC + FTC + TAF | NA | Not detected | 340 | 288 |
| 14 | TDF + LAM + EFV | NA | NA* | 155 | NA* |
| 15 | TDF + LAM + EFV | Not detected | Not detected | 121 | 206 |
TDF Tenofovir Disoproxil Fumarate; LAM Lamivudine; EFV Efavirenz; DTG Dolutegravir; BIC Bictegravir; FTC Emtricitabine; TAF Tenofovir Alafenamide Fumarate; RAL Raltegravir; NA Not Available
*Died or follow-up before response could be assessed